Vertex Pharmaceuticals Incorporated
VX1.DE
Deutsche Börse424.15
EUR
-24.90
- -
Vertex Pharmaceuticals Incorporated
VX1.DE
(Deutsche Börse)
Recent
price
424.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated is a global biotechnology company specializing in the discovery, development, and commercialization of innovative therapies primarily for serious diseases. The company’s main products include cystic fibrosis treatments, such as CFTR modulators branded under Trikafta, Kalydeco, Symdeko, and Orkambi; investigational medicines in oncology; precision medicines targeting rare genetic diseases; and inflammatory and pain management therapies. Vertex provides a comprehensive pipeline of small molecule drugs and gene editing programs through its research and development platforms, focusing heavily on transformative medicines. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex operates globally, with commercial presence primarily in the United States, Europe, Canada, and other select international markets. The company’s strategic partnerships and collaborations extend across pharmaceutical companies and research institutions to accelerate drug discovery and expand its therapeutic portfolio. Recent major company developments include strategic expansions in gene editing research, notably with advances in CRISPR-based therapies and continued investments in rare disease treatment platforms. In the last 1-2 years, Vertex has announced key collaborations to enhance its portfolio, including partnerships aimed at broadening its pipeline in pain management and oncology. Additionally, Vertex has expanded its manufacturing capabilities and increased product launches, enhancing access to its cystic fibrosis portfolio worldwide. No major name changes or reorganizations were reported, but the company continues strategic business development to solidify its leadership in specialty medicines. Thus, Vertex Pharmaceuticals Incorporated is a leading biotechnology firm dedicated to pioneering innovative therapies across multiple serious disease areas, with a robust commercial cystic fibrosis product line, a growing pipeline in rare diseases and oncology, and active collaborations enhancing its research and global market footprint.